About EyeYon
EyeYon is a company based in Ness Ziona (Israel) founded in 2011 by Nahum Ferera. EyeYon has raised $35.1 million across 3 funding rounds from investors including GF Securities, BPC Banking Tech and Quark Venture. EyeYon offers products and services including EndoArt® and Hyper-CL™. EyeYon operates in a competitive market with competitors including CorneaGen, Avedro, EyeGate, Cellusion and CorNeat Vision, among others.
- Headquarter Ness Ziona, Israel
- Founders Nahum Ferera
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35.1 M (USD)
in 3 rounds
-
Latest Funding Round
$25 M (USD), Series C
Mar 15, 2021
-
Investors
GF Securities
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EyeYon
EyeYon offers a comprehensive portfolio of products and services, including EndoArt® and Hyper-CL™.
Synthetic implant to treat corneal edema and replace donor tissues.
Contact lens that enhances bioavailability of topical eye drops for conditions.
People of EyeYon
Unlock access to complete
Funding Insights of EyeYon
EyeYon has successfully raised a total of $35.1M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EyeYon
EyeYon has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include GF Securities, BPC Banking Tech and Quark Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Sciences focused early stage VC firm investing in North America
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early stage healthcare startups
|
Locked | Locked | Locked | |
|
Limited information is provided about Rimonci's activities.
|
Locked | Locked | Locked |
Investor details for EyeYon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EyeYon
Investment portfolio details for EyeYon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EyeYon
Detailed financials for EyeYon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyeyon Comparisons
Peer comparison for EyeYon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EyeYon
EyeYon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Avedro, EyeGate, Cellusion and CorNeat Vision, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for corneal transplants are developed by CorneaGen.
|
|
| Locked | Locked | Locked |
Corneal collagen cross-linking technology is developed for ophthalmic applications.
|
|
| Locked | Locked | Locked |
Therapeutics and drug delivery systems for eye diseases are developed.
|
|
| Locked | Locked | Locked |
iPS cell-based technology for corneal endothelium regeneration is developed.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
Detailed competitors of EyeYon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyeyon
Complete news archive for EyeYon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyeYon
EyeYon was founded in 2011 and raised its 1st funding round 4 years after it was founded.
EyeYon is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Nahum Ferera is the current CEO of EyeYon. They have also founded this company.
EyeYon is a funded company, having raised a total of $35.1M across 3 funding rounds to date.
EyeYon was founded in 2011 in Ness Ziona, Israel, and operates in the ophthalmic medical device sector. Therapeutic contact lenses, such as the Hyper-CL, are developed for managing corneal pathologies. Additionally, the EndoArt implant, a polymer film attached to the posterior corneal surface, is created to address corneal edema resulting from endothelial dysfunction. Focus is placed on innovative solutions for eye-related conditions.
EyeYon offers EndoArt® and Hyper-CL™.
EyeYon has 8 investors. Key investors include GF Securities, BPC Banking Tech, Quark Venture, Triventures, and Rimonci.